Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

In the last few years, the treatment strategy in Non-Small Cell Lung Cancer (NSCLC) patients has been heavily modified by the introduction of the immune-checkpoint inhibitors. Anti-programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) therapy has improved both progression-free and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Santaniello, Antonio, Napolitano, Fabiana, Servetto, Alberto, De Placido, Pietro, Silvestris, Nicola, Bianco, Cataldo, Formisano, Luigi, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826622/
https://www.ncbi.nlm.nih.gov/pubmed/31554160
http://dx.doi.org/10.3390/cancers11101419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826622/
https://www.ncbi.nlm.nih.gov/pubmed/31554160
http://dx.doi.org/10.3390/cancers11101419

Ejemplares similares